Claritas Pharmaceuticals, Inc.
CLAZF · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $190 | $367 | $482 | $14 |
| - Cash | $2 | $282 | $28 | $5 |
| + Debt | $548 | $1,236 | $406 | $925 |
| Enterprise Value | $736 | $1,321 | $860 | $934 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $695 | $0 | -$2,718 | -$2,827 |
| % Margin | – | – | – | – |
| Net Income | $181 | -$1,944 | -$2,301 | -$654 |
| % Margin | – | – | – | – |
| EPS Diluted | 0.005 | -0.058 | -0.084 | -0.024 |
| % Growth | 108.8% | 30.4% | -246.9% | – |
| Operating Cash Flow | -$281 | $136 | -$324 | -$484 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$281 | $136 | -$324 | -$484 |